Skip to content

Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer

Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02950350
Enrollment
50
Registered
2016-11-01
Start date
2016-12-31
Completion date
2023-12-31
Last updated
2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Stage IIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage IIIB, Cervical Cancer, Stage IVA

Keywords

Cervical cancer, Precision medicine, Individualized treatment, Surgical staging

Brief summary

Cervical cancer is the most common reproductive malignancy in developing country. Due to local invasion, radical hysterectomy cannot be performed in advanced cervical cancer (FIGO IIB - IVA) , so that radiation combined with chemoradiation (RCTX) is a traditional treatment nowadays. Lack of precise treatment strategies, recurrent ratesand metastasisis high ,and the 5-year survival rate is less than 50%. Therefore, it needs to explore a new strategy for improving the prognosis of advanced cervical cancer. The prognosis of cervical cancer is closely related to its stages ,while the current FIGO clinical stage is too subjective , for example different gynecologic oncologists may give different diagnosis to the same patient. MRI, CT, PET/CT imaging examinations are commonly used as a referrence for clinical staging, but the sensitivity and specificity are not satisfied. In addition, lymph node metastasis significantly impacts the prognosis of cervical cancer . However, the lymph node invasion is not in current staging criteria. Precision treatment after surgical staging is recommended by NCCN recently .Surgical staging in patients with advancedcervical cancer is safe and does not delay primary RCTX in few randomized study.Whether overall survival benefit the long-term clinical follow-up surgical staging is unknown.Blocking bilateral uterine artery can effectively reduce the tumor size and increase the operability , which has been conformed in locally advanced cervical cancer. Furthermore, ovarian dysfunction caused by RCTX could be avoided by ovarian transposition via surgical staging . Based on this, we suggesta new surgical stagingfor patients with advanced cervical cancer , which includinglaparoscopic pelvic and para-aortic lymphadenectomy , uterine blood vessel blocking and ovarian transportation, in order to perform individualized postoperative RCTX, reduce tumor load , preserve ovarian function and improve life quality.

Interventions

None listed

Sponsors

Shanghai First Maternity and Infant Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Pathological diagnosis: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma * The pathological staging:IIB,IIIA,IIIB,IVA

Exclusion criteria

* Underwent surgery or radiation and chemotherapy

Design outcomes

Primary

MeasureTime frame
The recurrence rate5 years after treatment

Secondary

MeasureTime frame
The transfer rate5 years after treatment
mortality5 years after treatment

Contacts

Primary ContactXiaoqing Guo, PHD
xiaoqingguo333@163.com18117203488
Backup ContactNa Liu, PHD
1517693296@qq.com15601745699

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026